Last updated: 2026-09-16 09:06:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Mannkind Corporation (MNKD) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3,56, with a market capitalisation of $1,21B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2,23 to $6,51. This page covers its latest market performance, valuation, price trends and company information.
$1,21B | |
$3,55 | |
$121,55 | |
$0,67 | |
$3,56 | |
230,00 | |
4,46M | |
-- | |
$6,51 | |
$2,23 | |
-- | |
-- |
Mannkind Corporation (MNKD) is trading at $3,56 in pre-market trading as of 2026-09-16 08:41:00, down 0,03% ($0,00) from the previous close of $3,56
Pre-market trading shows how investors are pricing MNKD before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Mannkind Corporation (MNKD) moved from $4,06 to $3,56, representing a decline of 12,34% ($0,50).
The stock traded between $3,54 and $4,36 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 3,63 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 31,1%
MNKD is currently trading at $3,56, placing it 31,1% of the way from its 52-week low of $2,23 to its 52-week high of $6,51. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 592 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Mannkind Corporation (MNKD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.